UARK 98-026, Total Therapy II - A Phase III Study for Newly Diagnosed Multiple Myeloma Evaluating Anti-Angiogenesis With Thalidomide and Post-Transplant Consolidation Chemotherapy

NCT00083551 Phase 3 COMPLETED Results posted

This study has been designed to evaluate whether "anti-angiogenesis" therapy with thalidomide and whether additional chemotherapy after transplant will be beneficial. Another objective is to find out what kinds of side effects occur with this combination of treatment and how often they occur.

Details

Lead sponsor	University of Arkansas
Phase	Phase 3
Status	COMPLETED
Enrolment	668
Start date	1998-08
Completion	2014-08

Conditions

• Multiple Myeloma

Interventions

• Thalidomide
• Ara-C
• BCNU
• Cisplatin
• Cytoxan
• Dexamethasone
• Doxorubicin
• Etoposide
• Filgrastim
• Recombinant GM-CSF

Primary outcomes

• Overall Survival — 6 Years
  Overall Survival at six years after initiating protocol therapy

Countries

United States